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Last October, biologists’ neck-hair
rose when J. Craig Venter announced
his company, Celera, had filed 6,500
provisional patent applications for
human genes. Henry Ford
mass-produced automobiles — it
seems evident we are now entering
an era in which intellectual property
is rolling off the assembly lines. Is
this really the ultimate legacy of
Watson and Crick’s elegant double
helix? And what does it portend for
the future of biology? 
On April 22, 1996, Europe’s
patent office received an application
from a US company called Human
Genome Sciences, claiming the rights
to the entire genome of Haemophilus
influenzae. This patent also asserts the
right to that information in any
computer-readable form —
effectively preventing it from being
posted in any public database for any
scientific use. Scientists wanting to
interpret this genome and compare it
to others would have to resort to
paper and pencil — or presumably
pay for access to a private database.
Each of these cases is sobering in
its own way, and each raises
distinctly different issues. Consider
first the attempt to patent the entire
Haemophilus genome. Venter’s name
is on that patent — and his wife’s is
on a very similar application that
would cover the whole genome of
Mycoplasma genitalium. These patents
have not been issued, and it’s not
clear they will ever be. But the filing
of the patents cuts to the heart
of an issue surrounding
the patenting of genes:
just how much biology
should be turned
over to the private
ownership of individuals
and companies? 
The concept of patenting has
been around for centuries. The
original idea arose in England, where
patents were first used as a means to
lure printing presses into the
country, in exchange for a limited
monopoly on the printing
technology. Later, patents were used
to encourage guilds to reveal their
trade secrets; a monopoly right was
granted in exchange for information
that others could then use to
improve practices in science and the
practical arts. Indeed, few would
dispute that patents have
encouraged innovation. But some
gene patents are now testing the
limits of the patent system.
Intellectual property can now be
manufactured by the bushel
There is clearly a place for gene
patents, when the gene in question
is well characterized, and when
there is a clear use for the
information. Patents, after all, must
satisfy three basic criteria: the
invention must be novel; it must not
be obvious; and it must be useful.
Michael Morgan, at the Wellcome
Trust, helped craft the most
restrictive (albeit voluntary)
guidelines for gene patenting — the
‘Bermuda Agreement,’ which
stipulates that the raw data from the
Human Genome Project will be
placed immediately in the public
domain and therefore not subject to
patenting. He and his US colleague
Francis Collins (head of the Human
Genome Project) agree that it is
appropriate in some circumstances
— such as when there’s a clear,
immediate use — to patent genes.
Collins is even the ‘inventor’ of the
genes for cystic fibrosis and
neurofibromatosis, to name two.
The sticky bit comes, however,
when a claim lacks an obvious use.
The US Patent office has approved a
few patents for mere gene
fragments — where the ‘utility’ is
essentially as scientific probes to
find related genes.
It’s one thing to patent tools.
Shouldn’t the inventor of the
electron microscope be granted some
consideration for his creativity?
Likewise, shouldn’t the ‘inventor’
(that’s the word the patent offices
use) of restriction enzymes be
granted some reward — in exchange
for telling the world exactly what the
invention is and how it works? But
some of these new gene patents have
an insidious nature to them. True,
they are tools that can be used to
discover more genes. But in this case,
inventors can assert that the new
discoveries are, in effect, an
extension of their tools — therefore
also part of their intellectual
property. It’s as though the inventor
of the electron microscope could also
claim all the discoveries made with
that instrument. 
Collins has argued that the US
Patent and Trademark office has
been too lax in granting patents on
the basis of their utility as research
tools (see green box). The patent
office reconsidered its utility
guidelines for genes and tightened
them somewhat last December. By
and large, gene fragments are no
longer considered useful (or
patentable). But if an inventor can
identify a gene, a gene product, and
state a use, the office will issue a
patent. And useful in this case
doesn’t have to mean potentially
therapeutic or valuable in the
laboratory. A ‘use’ is simply
describing how the gene product
functions in nature which — from a
practical standpoint — is to say not
necessarily useful at all. These
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revised guidelines will not have
much of an effect on the 10,000 or so
gene patents now pending in the US.
Patent office officials figure only
about 500 patents will be rejected in
their current form.
Which brings us back to Henry
Ford. A few companies — notably
Human Genome Sciences, Celera
and Incyte Pharmaceuticals — claim
to have thousands of patents
pending. Some are mere place
holders — Celera’s ‘provisional’
patent applications expire 12 months
after they are issued, so the
company will need to pick and choose
which are actually worth the trouble
of fleshing out and filing in earnest.
Venter asserts he will only hold a few
hundred patents on human genes
when all is said and done. 
But this patent gold-rush has
disturbing consequences for
biologists. Part of it is uncertainty
about how these patents could
complicate their research. Academic
freedom does not extend to using
other people’s intellectual
property — a patent holder has a right
to exclude anyone from using his or
her invention. Historically, academics
have not been prevented from using
patented genes — indeed, companies
often have a strong financial incentive
to let others discover more about their
patented material because it increases
the value of the patent. But the
moment money changes hands, say at
an academic genetics lab, patent
holders are quick to step in and
assert their rights.
Necessity is not the mother of
these inventions
And it is ironic that in some of the
most celebrated cases regarding gene
patents, the villains turn out to be
academic institutions. Allen Roses,
now senior vice president of genetics
research at Glaxo SmithKline,
discovered that people who carry the
ApoE4 allele are at greater risk for
developing Alzheimer’s disease.
Duke University, where Roses made
that discovery, licensed that patented
discovery exclusively to a small
biotechnology company, which is now
trying to turn a profit by marketing
that test and others like it. That galls
the folks in academic genetics labs,
who were told to stop offering their
own versions of the ApoE4 test (at
considerably lower cost). 
William Haseltine, chairman and
CEO of Human Genome Sciences,
argues the whole patent issue has
been overblown. He says, for
example, more than 1,000 patents
have been issued in connection with
HIV, yet research on AIDS has hardly
been choked. Indeed, Haseltine says
the US Government holds a patent
on what amounts to the whole AIDS
virus — that’s the basis of the ELISA
assay that was hotly contested with
the Institut Pasteur.
But there is a deeper issue here.
Academic researchers who used to
labor for years to discover and
understand the basics of a single gene
are aghast to discover that intellectual
property can now be manufactured
by the bushel barrel. Mostly what it
requires is some DNA sequencers, a
cadre of PhDs and a computer
algorithm that can spot homologies
between novel stretches of DNA and
sequences of known function. Presto,
a gene patent is born, and is the
exclusive provenance of its owner for
at least 17 years.
Necessity is not the mother of
these inventions — indeed, the
proud parents usually intend to put
them up on the auction block as
quickly as possible. And many
orphans are likely to languish. The
other part of the social
contract — public disclosure — is
more frequently taking place in
patent filings rather than the pages of
peer-reviewed journals. Patent office
websites are rapidly becoming an
internet destination to rival PubMed. 
It seems inevitable now that most
useful human genes will be covered
by patents. But even the big drug
companies have found a limit to the
gene-patenting craze. Ten of the
pharmaceutical giants have joined
with the Wellcome Trust to
collaborate in finding hundreds of
thousands of single-base mutations
in DNA (single nucleotide
polymorphisms or SNPs). They will
try to patent this SNP data, as it
could be a valuable tool for
discovering genetic variations that
correlate with common diseases. But
they have decided that they will not
enforce the patents (if, indeed, they
receive them). The patents would
simply prevent others from locking
up this information for their private
use. In this case, at least, they have
decided that genetic information
best serves its masters by being free.
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Gene patents issued by the US Patent
and Trademark Office as of year-end 1999
Holder No. of patents 
US Government 388
Incyte Pharmaceuticals 356
University of California 265
SmithKline Beecham 197
Genentech 175
Eli Lilly 145
Novo Nordisk 142
Chiron 129
American Home Products 117
Isis Pharmaceuticals 108
Mass. General Hospital 108
Human Genome Sciences 104
University of Texas 103
Institut Pasteur 101
Source: PricewaterhouseCoopers.
Patents typically take three years to issue.
European patents are revealed 18 months
after they are submitted and while they
are still pending. The US is adopting to a
similar system. Pending patents are not
included in the above chart.
The patent gold rush
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